Circulating levels of novel adipocytokines in patients with colorectal cancer

Cytokine

Volumn 62, Issue 1, 2013, Pages 81-85

  Fazeli, Mohammad Sadegh ^a   Dashti, Habibollah ^a,b   Akbarzadeh, Samad ^b   Assadi, Majid ^b   Aminian, Ali ^a   Keramati, Mohammad Reza ^a   Nabipour, Iraj ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adipocytokines; Colorectal cancer; Omentin 1; Vaspin; Visfatin

Indexed keywords

ADIPOCYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN 1; UNCLASSIFIED DRUG; VASPIN;

ADULT; AGE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; WAIST HIP RATIO;

ADIPOKINES; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SERPINS;

EID: 84875766925     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.02.012     Document Type: Article

References (46)

1. Kant P., Hull M.A. Excess body weight and obesity - the link with gastrointestinal and hepatobiliary cancer. Nat Rev Gastroenterol Hepatol 2011, 8:224-238.
2. Doyle S.L., Donohoe C.L., Lysaght J., Reynolds J.V. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc 2011, 3:1-9.
3. Calle E.E., Thun M.J. Obesity and cancer. Oncogene 2004, 23:6365-6378.
4. Schaffler A., Neumeier M., Herfarth H., Furst A., Scholmerich J., Buchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005, 1732:96-102.
5. Yamaji T., Iwasaki M., Sasazuki S., Tsugane S. Interaction between adiponectin and leptin Influences the risk of colorectal adenoma. Cancer Res 2010, 70:5430-5437.
6. Otake S., Takeda H., Fujishima S., et al. Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol 2010, 16:1252-1257.
7. Salageanu A., Tucureanu C., Lerescu L., et al. Serum levels of adipokinesresistin and leptin in patients with colon cancer. J Med Life 2010, 3:416-420.
8. Fenton J.I., Birmingham J.M. Adipokine regulation of colon cancer: adiponectin attenuates interleukin-6-induced colon carcinoma cell proliferation via STAT-3. Mol Carcinogen 2010, 49:700-709.
9. Nakajima T.E., Yamada Y., Hamano T. L. Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010, 101:1286-1291.
10. Kumor A., Daniel P., Pietruczuk M., Malecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis 2009, 24:275-281.
11. Boddicker R.L., Whitley E., Birt D.F., Spurlock M.E. Early Lesion formation in colorectal carcinogenesis is associated with adiponectin status whereas neoplastic lesions are associated with diet and sex in C57BL/6J mice. Nutr Cancer 2011, 63:1297-1306.
12. Endo H., Hosono K., Uchiyama T., et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut 2011, 60:1363-1371.
13. Byeon J.S., Jeong J.Y., Kim M.J., et al. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer 2010, 127:2758-2767.
14. Kim A.Y., Lee Y.S., Kim K.H., et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 2010, 24:1441-1452.
15. Fujisawa T., Endo H., Tomimoto A., et al. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 2008, 57:1531-1538.
16. Guadagni F., Roselli M., Martini F., et al. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res 2009, 29:3321-3327.
17. Fukuhara A., Matsuda M., Nishizawa M., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
18. Bi T.Q., Che X.M. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 2010, 10:119-125.
19. Garten A., Petzold S., Körner A., Imai S.-i., Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009, 20:130-138.
20. Reddy P.S., Umesh S., Thota B., et al. PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther 2008, 7:663-668.
21. Shackelford R.E., Bui M.M., Coppola D., Hakam A. Over-expression of nicotinamidephosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol 2010, 3:522-527.
22. Hufton S.E., Moerkerk P.T., Brandwijk R., de Bruïne A.P., Arends J.-W., Hoogenboom H.R. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 1999, 463:77-82.
23. Nakajima T.E., Yamada Y., Hamano T., et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009, 44:685-690.
24. Yang R.Z., Lee M.J., Hu H., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-E1261.
25. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Inv Drug 2008, 17:327-333.
26. Nabipour I., Amiri M., Imami S.R., et al. The metabolic syndrome and nonfatal ischemic heart disease; a population-based study. Int J Cardiol 2007, 118:48-53.
27. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-97.
28. The American Joint Committee on Cancer AJCC cancer staging handbook 2010, Springer, New York. 7th ed.
29. van Beijnum J.R., Moerkerk P.T.M., Gerbers A.J., et al. Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer 2002, 101:118-127.
30. Gallí M., Van Gool F., Rongvaux A., Andris F., Leo O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res 2010, 70:8-11.
31. Berndt J., Klöting N., Kralisch S., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005, 54:2911-2916.
32. Hofsø D., Ueland T., Hager H., et al. Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. Eur J Endocrinol 2009, 161:451-458.
33. Akbarzadeh S., Nabipour I., Jafari S.M., et al. Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2012, 95:132-138.
34. Chang Y.C., Chang T.J., Lee W.J., Chuang L.M. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamidephosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism 2010, 59:93-99.
35. de Souza Batista C.M., Yang R.Z., Lee M.J., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661.
36. Tan B.K., Adya R., Farhatullah S., et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808.
37. Tan B.K., Adya R., Farhatullah S., Chen J., Lehnert H., Randeva H.S. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome. Diabetes 2010, 59:3023-3031.
38. Chen J., Somanath P.R., Razorenova O., et al. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med 2005, 11:1188-1196.
39. Somanath P.R., Razorenova O.V., Chen J., Byzova T.V. Akt1 in endothelial cell and angiogenesis. Cell Cycle 2006, 5:512-518.
40. Itoh N., Semba S., Ito M., Takeda H., Kawata S., Yamakawa M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002, 94:3127-3134.
41. Lim K.-H., Ancrile B.B., Kashatus D.F., Counter C.M. Tumour maintenance is mediated by eNOS. Nature 2008, 452:646-649.
42. Yeh C.C., Santella R.M., Hsieh L.L., Sung F.C., Tang R. An intron 4 VNTR polymorphism of the endothelial nitric oxide synthase gene is associated with early-onset colorectal cancer. Int J Cancer 2009, 124:1565-1571.
43. Burgering B.M., Coffer P.J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376:599-602.
44. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-532.
45. Hida K., Wada J., Eguchi J., et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005, 102:10610-10615.
46. Jung C.H., Lee W.J., Hwang J.Y., et al. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun 2011, 413:264-269.